Cure Today19h
A Phase 1 Trial of Iadademstat Plus Vidaza Has Dosed a Patient With MDS
The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...
emjreviews.com4d
Impact of TP53 Alterations on Myelodysplastic Prognosis
Study examines the effect of TP53 mutations on outcomes in MDS patients receiving haploidentical haematopoietic stem cell ...
oncnursingnews5d
FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
Johns Hopkins Medicine6d
Cushing's Syndrome
What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...
Cure Today6d
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...
Targeted Oncology6d
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...
Medscape6d
FDA Approves Grafapex (Treosulfan) for HSCT Conditioning
After a delayed approval, treosulfan’s manufacturer is hopeful the alkylating agent will become the new gold standard in the United States.
Opinion
The Clermont Sun6dOpinion
Op-Ed: K2 Disabled Veterans Finally Receive Justice
On January 8, 2025, the Department of Veterans Affairs (VA) announced it was adding eight (8) new presumptives for disabled veterans. These new presumptives are: acute and chronic ...